Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Rate of admission to ICU of patients with PID affected by COVID-19
Study Overview
Brief Summary
With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID).
Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19".
COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password.
Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 0 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed with a Primary Immune Deficiency
- •COVID-19 (proven or probable)
Exclusion Criteria
- •Secondary Immune Deficiency
- •Other Coronovirus infection
Outcomes
Primary Outcomes
Rate of admission to ICU of patients with PID affected by COVID-19
Time Frame: Baseline
Survival of patients with PID affected by COVID-19
Time Frame: Baseline
Rate of oxygen therapy of patients with PID affected by COVID-19
Time Frame: Baseline
Secondary Outcomes
- Sequelae of patients with PID affected by COVID-19(Baseline)